WASHINGTON, June 19, 2013 /PRNewswire-USNewswire/ -- Genomic medicine has the potential to be a cornerstone of medical testing, treatment, and clinical integration. Without doubt, the Supreme Court's unanimous decision invalidating Myriad's patents on BRCA1 and BRCA2 is already changing the testing landscape for those genes. What other changes can we expect? How will the decision impact medical testing? What did it take to win the case? (Logo: http://photos.prnewswire.com/prnh/20120314/DC69899LOGO-a ) As a co-plaintiff in this landmark case, the CAP and all pathologists have cause to celebrate the Court's ruling. The CAP has assembled a panel of leading experts, including the researcher who...
↧